RD-X19

DEVICE4 trials

Sponsors

EmitBio Inc., David Moss

Conditions

COVID-19COVID-19 Respiratory InfectionCOVID19Influenza

Unknown Phase

Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19

CompletedNCT04662671

EmitBio Inc.COVID19

Start: 2020-11-18End: 2021-01-30Updated: 2022-09-08

Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19

CompletedNCT04966013

EmitBio Inc.COVID19

Start: 2021-06-17End: 2022-02-23Updated: 2024-09-19

Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

CompletedNCT05817045

EmitBio Inc.COVID-19

Start: 2023-04-21End: 2024-06-30Updated: 2024-10-24

Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections

Not yet recruitingNCT07610967

David MossCOVID-19 Respiratory Infection, Influenza

Start: 2026-10-01End: 2028-06-01Target: 130Updated: 2026-08-26